Guideline/Drug Updates and Errata

RxPrep content (e.g., NAPLEX Course Book, MPJE/CPJE Manuals and Test Banks) is up-to-date at the time of publishing, but drug information and laws can change at any time. If information changes after a product is published, we will post exam-relevant updates in the Guideline/Drug Updates tables below. If we find anything that needs a correction or clarification it will be included in the Errata tables below. Click on the button for the content you are studying:

NAPLEX


Guideline/Drug Updates: 2022 RxPrep Course Book

NAPLEX-relevant updates from June 2021-May 2022

Page Update Type Description
Chapter 18: Renal Disease and Chapter 44: Diabetes
p. 292, 617 Labeling Change

Dapagliflozin (Farxiga) has been FDA-approved for adults with chronic kidney disease to reduce the risk of eGFR decline, end-stage renal disease, cardiovascular death and hospitalization for heart failure.

Chapter 23: Infectious Diseases II: Bacterial Infections
p. 393 Guideline Update

The Infectious Diseases Society of America (IDSA) and the American College of Gastroenterologists (ACG) have both released updates for the treatment of Clostridioides difficile infection (CDI):

  • First (initial) episode: preferred first-line treatment options remain the same (fidaxomicin or oral vancomycin).
  • Second episode (first recurrence): can be treated with any of the following regardless of the antibiotic used for the initial episode (unless noted):
    • Fidaxomicin 200 mg PO BID x 10 days
    • Vancomycin tapered and pulsed regimen (e.g., vancomycin 125 mg PO QID for 10 days, then BID for one week, then once per day for one week, then every 2 or 3 days for 2-8 weeks)
    • Vancomycin 125 mg PO QID x 10 days (if metronidazole was used to treat the initial episode)
  • Subsequent episodes: treatment options for the third episode or greater remain the same.
  • Bezlotoxumab has a more defined role in the prevention of recurrent CDI. It can be considered in high risk patients (e.g., age ≥ 65, immunocompromised, severe presentation and/or a second episode within the past 6 months) and must be used in combination with antibiotics active against C. difficile (e.g., fidaxomicin or oral vancomycin). A labeled warning advises caution when used in patients with a history of heart failure.
p. 394 Guideline Update

The Sexually Transmitted Infections Treatment Guidelines, 2021 published by the Centers for Disease Control and Prevention contain an update for chlamydia treatment. The preferred regimens are:

  • Non-pregnant adults: doxycycline 100 mg PO BID x 7 days
  • Pregnant females: azithromycin 1 gram PO x 1 dose
Chapter 31: Chronic Heart Failure and Chapter 44: Diabetes
p. 482, 617 Labeling Change

Empagliflozin (Jardiance) has been FDA-approved to reduce the risk of cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction.

Chapter 34: Anticoagulation
p. 523 Guideline Update

The American College of Chest Physicians (CHEST) released a second update to the Antithrombotic Therapy for the Treatment of Venous Thromboembolism (VTE) Disease guideline:

  • In patients with cancer-associated thrombosis, oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are preferred over low molecular weight heparins (e.g., enoxaparin).
Chapter 44: Diabetes and Chapter 57: Weight Loss
p. 618, 756 Labeling Change

Semaglutide (Wegovy) injection has been FDA-approved for weight management in adults with obesity or who are overweight with at least one additional weight-related condition (e.g., hypertension, type 2 diabetes, dyslipidemia).

Errata: 2022 RxPrep Course Book

Corrections or clarifications for the 2022 RxPrep Course Book

Page Description
Chapter 15: Compounding I
p. 246

On the clipboard describing USP 797 cleaning requirements, the minimum frequency of cleaning the carts should be monthly.

Chapter 18: Renal Disease
p. 293

In the section under Collecting Duct, the second to last sentence in the paragraph should say, “Potassium-sparing diuretics (including aldosterone antagonists) work in the distal convoluted tubule and collecting duct to decrease Na and water reabsorption and increase K reabsorption.

View 2021 RxPrep Course Book Guideline/Drug Updates and Errata

MPJE/CPJE


MPJE Updates: 7th Edition Federal Law Summary for MPJE

MPJE-relevant updates from January 2021-Present

Page Update Type Description
Chapter 3: Pharmacy Operations
p. 44 DEA Update

Effective October 2020

All controlled substances (schedule II – V) can be stored in a locked cabinet or dispersed among other drugs. Prior to this change, schedule II drugs needed to be stored in a securely locked cabinet or vault and could not be dispersed throughout the stock of non-controlled drugs.

Chapter 4: Pharmacy Practice
p. 77 Interchangeable Biosimilar Approval

Effective July 2021

The FDA has approved the first interchangeable biosimilar, Semglee (insulin glargine-yfgn), as a substitute for Lantus (insulin glargine). The approval allows for substitution of the biosimilar for Lantus at the pharmacy without the need for a separate prescription.

MPJE Errata: 7th Edition Federal Law Summary for MPJE

Corrections or clarifications for the 7th Edition Federal Law Summary for MPJE

Page Description
Chapter 4: Pharmacy Practice
p. 65

Regarding the prescription drugs that do not require child-resistant packaging, colesevelam powder should read ≤ 3.75 grams/package.

Chapter 8: Controlled Substances Part 3: Prescribing and Dispensing
p. 154

The 4th bullet in the Methadone Study Tip should read “(days 271 - 365).”

CPJE Updates: 7th Edition California Law Summary for CPJE

CPJE-relevant updates from January 2021-Present

Page Update Type Description
Chapter 3: Pharmacy Practice Part I
p. 52 Interchangeable Biosimilar Approval

Effective July 2021

The FDA has approved the first interchangeable biosimilar, Semglee (insulin glargine-yfgn), as a substitute for Lantus (insulin glargine). The approval allows for substitution of the biosimilar for Lantus at the pharmacy without the need for a separate prescription.

Chapter 7: Controlled Substances Part 3: Prescribing and Dispensing
p. 120 & 121 Revised California Security Forms

Effective January 1, 2021

The following updates were made to secure prescription form requirements:

  • In addition to the features noted on p. 120 and 121, security prescription forms must now contain a barcode and the prescriber's pre-printed address.
  • The serial number formatting has also changed from 15 digits (3 letters followed by 12 numbers) to 12 digits (any combination of letters and numbers) that corresponds with the barcode.

Download the RxPrep App

Take your studies with you wherever you go.

Take RxPrep for a Test Drive!

Create an account to explore the features of our site, sample our products and take our two FREE Assessment Tests.